Zong Li, Chun-Yan Chen M, Dong‐sheng Zhang, Shui-qing Zhuo, Guixiao Xu, Dele Deng, Haibin Liu, B. Liang, Zhixing Lin, Xiao-ting Zhang, Wenxin Zhong, Junyang Huang, C. Xie, Yi-zhuo Li, Hao-qiang He
Objectives: To try another non-invasive method to evaluate the relationship between Magnetic Resonance (MR) elastic value and pathological grade of Hepatocellular Carcinoma (HCC) using Magnetic Resonance Elastography (MRE). Methods: Forty-seven HCC patients underwent MR Imaging (MRI), elastography in the upper abdomen. The elastic value of the lesion area was measured, and that of the normal liver tissue was measured adjacent to the lesion area at the same level. The Mann-Whitney U test was used to compare the difference in elasticity between the lesion area and normal area, and the difference between the low and middle-high differentiation groups. The Receiver Operating Characteristic Curve (ROC) of the lesion area and normal area in the complete case group and different differentiation groups were used to determine the diagnostic cut-off value to distinguish the lesion area from the normal area in each group. Results: (1) There was a significant difference in elasticity between the normal area and HCC area (p<0.001). The diagnostic cut-off value was 4842 Pa. (2) There was a significant difference in elasticity between the low-and middle-high differentiation groups (p<0.001). The diagnostic cut-off value was 10456 Pa. (3) There was a statistically significant correlation between the elastic value on MRE and degree of pathological differentiation of HCC in the two groups (p<0.001). Conclusion: The elastic value of HCC measured using MRE can be used to evaluate the degree of pathological differentiation of HCC. MRE may be a non-invasive and reliable method for evaluating the pathological grade of HCC.
{"title":"Quantitative Evaluation of the Relationship between Magnetic Resonance Elastic Value and Pathological Grade of Hepatocellular Carcinoma by Magnetic Resonance Elastography","authors":"Zong Li, Chun-Yan Chen M, Dong‐sheng Zhang, Shui-qing Zhuo, Guixiao Xu, Dele Deng, Haibin Liu, B. Liang, Zhixing Lin, Xiao-ting Zhang, Wenxin Zhong, Junyang Huang, C. Xie, Yi-zhuo Li, Hao-qiang He","doi":"10.25107/cio-v6-id1873","DOIUrl":"https://doi.org/10.25107/cio-v6-id1873","url":null,"abstract":"Objectives: To try another non-invasive method to evaluate the relationship between Magnetic Resonance (MR) elastic value and pathological grade of Hepatocellular Carcinoma (HCC) using Magnetic Resonance Elastography (MRE). Methods: Forty-seven HCC patients underwent MR Imaging (MRI), elastography in the upper abdomen. The elastic value of the lesion area was measured, and that of the normal liver tissue was measured adjacent to the lesion area at the same level. The Mann-Whitney U test was used to compare the difference in elasticity between the lesion area and normal area, and the difference between the low and middle-high differentiation groups. The Receiver Operating Characteristic Curve (ROC) of the lesion area and normal area in the complete case group and different differentiation groups were used to determine the diagnostic cut-off value to distinguish the lesion area from the normal area in each group. Results: (1) There was a significant difference in elasticity between the normal area and HCC area (p<0.001). The diagnostic cut-off value was 4842 Pa. (2) There was a significant difference in elasticity between the low-and middle-high differentiation groups (p<0.001). The diagnostic cut-off value was 10456 Pa. (3) There was a statistically significant correlation between the elastic value on MRE and degree of pathological differentiation of HCC in the two groups (p<0.001). Conclusion: The elastic value of HCC measured using MRE can be used to evaluate the degree of pathological differentiation of HCC. MRE may be a non-invasive and reliable method for evaluating the pathological grade of HCC.","PeriodicalId":91853,"journal":{"name":"Clinics in oncology (Belmont, Calif.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80460974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-21DOI: 10.21203/rs.3.rs-900438/v1
Pengcheng Yang, Y. Chu, Qian Li, Tianyu Lei, Jia Song, T. Ning, Q. Hu
Background: The effect of contralateral prophylactic mastectomy (CPM) on the survival rate of triple-negative breast cancer (TNBC) patients is still controversial. The purpose of this study was to confirm whether unilateral TNBC patients benefit from CPM.Methods: 10006 patients with unilateral TNBC in the Surveillance, Epidemiology and End Results (SEER) database were enrolled in this study, propensity score matching (PSM) was applied to balance patient assignments. After PSM,3039 pairs of patients were divided into a CPM group and no-CPM group, respectively. All the patients have undergone total mastectomy or radical mastectomy. Cox proportional hazards regression models were used to evaluate overall survival (OS) and breast cancer-specific survival (BCSS) of the two groups. Subgroup analysis was introduced to exclude the effect of confounding factors. To identify potential variables for prognosis, Kaplan–Meier survival analysis and Cox regression analysis were used and were presented by Kaplan–Meier curve and forest plot separately.Results: With a median follow‐up time of 34.5months (IQR 1–83 months), the estimated 5-year BCSS rates for patients in the CPM group and the no-CPM group were 81.96% and 78.71%, the 5-year OS rates were 80.10% and 75.05%, respectively. CPM improved the BCSS (hazard ratio [HR]= 0.79; 95% confidence interval [CI]=0.69-0.90, p=0.001) and OS (HR= 0.74; 95% CI=0.66-0.84, p<0.001) of unilateral TNBC patients. Univariate subgroup analyses revealed that there was no significant difference in survival time for patients in stage N3 who underwent CPM or not (p>0.05).Conclusions: CPM only limitedly improved BCSS and OS in patients with unilateral TNBC undergoing total mastectomy or radical mastectomy and was not recommended for stage N3 patients.
{"title":"Contralateral Prophylactic Mastectomy Improves Survival Only Marginally in Patients with Unilateral Triple-Negative Breast Cancer: A Cohort Study Based on SEER Database","authors":"Pengcheng Yang, Y. Chu, Qian Li, Tianyu Lei, Jia Song, T. Ning, Q. Hu","doi":"10.21203/rs.3.rs-900438/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-900438/v1","url":null,"abstract":"\u0000 Background: The effect of contralateral prophylactic mastectomy (CPM) on the survival rate of triple-negative breast cancer (TNBC) patients is still controversial. The purpose of this study was to confirm whether unilateral TNBC patients benefit from CPM.Methods: 10006 patients with unilateral TNBC in the Surveillance, Epidemiology and End Results (SEER) database were enrolled in this study, propensity score matching (PSM) was applied to balance patient assignments. After PSM,3039 pairs of patients were divided into a CPM group and no-CPM group, respectively. All the patients have undergone total mastectomy or radical mastectomy. Cox proportional hazards regression models were used to evaluate overall survival (OS) and breast cancer-specific survival (BCSS) of the two groups. Subgroup analysis was introduced to exclude the effect of confounding factors. To identify potential variables for prognosis, Kaplan–Meier survival analysis and Cox regression analysis were used and were presented by Kaplan–Meier curve and forest plot separately.Results: With a median follow‐up time of 34.5months (IQR 1–83 months), the estimated 5-year BCSS rates for patients in the CPM group and the no-CPM group were 81.96% and 78.71%, the 5-year OS rates were 80.10% and 75.05%, respectively. CPM improved the BCSS (hazard ratio [HR]= 0.79; 95% confidence interval [CI]=0.69-0.90, p=0.001) and OS (HR= 0.74; 95% CI=0.66-0.84, p<0.001) of unilateral TNBC patients. Univariate subgroup analyses revealed that there was no significant difference in survival time for patients in stage N3 who underwent CPM or not (p>0.05).Conclusions: CPM only limitedly improved BCSS and OS in patients with unilateral TNBC undergoing total mastectomy or radical mastectomy and was not recommended for stage N3 patients.","PeriodicalId":91853,"journal":{"name":"Clinics in oncology (Belmont, Calif.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73787737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Inflammation, Oxidative Stress and Cobalt Deficiency in Acute Childhood Leukemia","authors":"M. Akiibinu, B. Oseni, A. Adesiyan, S. Akiibinu, J. Anetor","doi":"10.25107/2474-1663-v4-id1663","DOIUrl":"https://doi.org/10.25107/2474-1663-v4-id1663","url":null,"abstract":"*Correspondence: Moses O Akiibinu, Department of Chemistry and Biochemistry, Caleb University Lagos, G.P.O Box 11379 Dugbe, Ibadan, Oyo state, Nigeria, E-mail: akiibinumoses@yahoo.com Received Date: 05 Sep 2019 Accepted Date: 27 Sep 2019 Published Date: 10 Oct 2019 Citation: Akiibinu MO, Oseni BS, Adesiyan AA, Anetor JI. Inflammation, Oxidative Stress and Cobalt Deficiency in Acute Childhood Leukemia. Clin Oncol. 2019; 4: 1663.","PeriodicalId":91853,"journal":{"name":"Clinics in oncology (Belmont, Calif.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80202294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-03-21DOI: 10.25107/2474-1663.ID1596
A. Macciò, G. Chiappe, Fabrizio Lavra, E. Sanna, C. Madeddu
Since 1993, when the first Total Laparoscopic Hysterectomy (TLH) was described, surgical treatment for uterine fibroids has changed significantly. Initially, surgeons discussed the feasibility and safety of TLH compared with vaginal and laparotomy approaches. Presently, surgeons are working to better understand the limits of TLH, especially relative to its complexity, when associated with particular clinical conditions, such as presence of adnexal masses, adhesions, endometriosis, and in terms of the size of the uterus to be removed. In recent years, we have been attempting to demonstrate that expert teams can successfully perform TLH of large-sized uteri that were once removed only by laparotomy [1,2]. In 2016, in a large series of large uteri removed laparoscopically, we reported a maximum uterine weight of 4000 g [3]. Subsequently, we described the possibility of laparoscopically removing a uterus weighing 5320 g with the support of a uterine manipulator [4] as well as a uterus weighing 5720 g without the aid of a uterine manipulator [5], both with no complications. Thus far, the weight limit of a uterus that can be removed laparoscopically and the possible complications of such a surgery remain unclear. Here, we describe an 80-year-old patient who underwent laparoscopic removal of a huge uterine mass with cystic degeneration weighing 11000 g.
{"title":"Removal of a Huge Uterine Mass, Weighing 11000 Grams, In an Elderly Woman with a Minimally Invasive Surgical Approach: Feasibility and Safety","authors":"A. Macciò, G. Chiappe, Fabrizio Lavra, E. Sanna, C. Madeddu","doi":"10.25107/2474-1663.ID1596","DOIUrl":"https://doi.org/10.25107/2474-1663.ID1596","url":null,"abstract":"Since 1993, when the first Total Laparoscopic Hysterectomy (TLH) was described, surgical treatment for uterine fibroids has changed significantly. Initially, surgeons discussed the feasibility and safety of TLH compared with vaginal and laparotomy approaches. Presently, surgeons are working to better understand the limits of TLH, especially relative to its complexity, when associated with particular clinical conditions, such as presence of adnexal masses, adhesions, endometriosis, and in terms of the size of the uterus to be removed. In recent years, we have been attempting to demonstrate that expert teams can successfully perform TLH of large-sized uteri that were once removed only by laparotomy [1,2]. In 2016, in a large series of large uteri removed laparoscopically, we reported a maximum uterine weight of 4000 g [3]. Subsequently, we described the possibility of laparoscopically removing a uterus weighing 5320 g with the support of a uterine manipulator [4] as well as a uterus weighing 5720 g without the aid of a uterine manipulator [5], both with no complications. Thus far, the weight limit of a uterus that can be removed laparoscopically and the possible complications of such a surgery remain unclear. Here, we describe an 80-year-old patient who underwent laparoscopic removal of a huge uterine mass with cystic degeneration weighing 11000 g.","PeriodicalId":91853,"journal":{"name":"Clinics in oncology (Belmont, Calif.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82578943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alexandra L Tabakin, Michael A Weintraub, Kushan D Radadia, Cristo G Salazar, Evita Sadimin, Eric A Singer
Paragangliomas are rare neuroendocrine tumors with 500 to 1600 new cases in the United States each year (1). The clinical presentation may range from asymptomatic to the classic triad of episodic diaphoresis, headache, and palpitations. Surgery is the hallmark of treatment when tumors are amenable to resection. When patients are found to have metastases, systemic therapies may be employed. In this case report, we present a patient found to have a large retroperitoneal paraganglioma with nodal metastases.
{"title":"Metastatic retroperitoneal paraganglioma: Case report and review of the literature.","authors":"Alexandra L Tabakin, Michael A Weintraub, Kushan D Radadia, Cristo G Salazar, Evita Sadimin, Eric A Singer","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Paragangliomas are rare neuroendocrine tumors with 500 to 1600 new cases in the United States each year (1). The clinical presentation may range from asymptomatic to the classic triad of episodic diaphoresis, headache, and palpitations. Surgery is the hallmark of treatment when tumors are amenable to resection. When patients are found to have metastases, systemic therapies may be employed. In this case report, we present a patient found to have a large retroperitoneal paraganglioma with nodal metastases.</p>","PeriodicalId":91853,"journal":{"name":"Clinics in oncology (Belmont, Calif.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554718/pdf/nihms-1028765.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40542414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ewing sarcoma is a predominantly paediatric cancer with a high rate of metastasis and reoccurrence. A new surface marker called LINGO-1 was recently identified on Ewing tumours as a potential target for antibody-mediated therapies. However, such targeting requires caution because of LINGO-1 expression on some brain cells. Although the blood-brain-barrier exists, small amounts of antibody may cross this barrier and cause harmful side-effects. In this perspective, we suggest some options to alleviate this risk that can make targeting tumour cells expressing the LINGO-1 antigen a safe option.
{"title":"LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma.","authors":"Arvind Jain, Jing Zhang, Terence Rabbitts","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Ewing sarcoma is a predominantly paediatric cancer with a high rate of metastasis and reoccurrence. A new surface marker called LINGO-1 was recently identified on Ewing tumours as a potential target for antibody-mediated therapies. However, such targeting requires caution because of LINGO-1 expression on some brain cells. Although the blood-brain-barrier exists, small amounts of antibody may cross this barrier and cause harmful side-effects. In this perspective, we suggest some options to alleviate this risk that can make targeting tumour cells expressing the LINGO-1 antigen a safe option.</p>","PeriodicalId":91853,"journal":{"name":"Clinics in oncology (Belmont, Calif.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36839548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"NMR Metabolomics in Ionizing Radiation.","authors":"Jian Zhi Hu, Xiongjie Xiao, Mary Y Hu","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":91853,"journal":{"name":"Clinics in oncology (Belmont, Calif.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35169273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：